大流行
2019年冠状病毒病(COVID-19)
接种疫苗
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
信使核糖核酸
病毒学
大规模疫苗接种
临床试验
2019-20冠状病毒爆发
医学
作者
Lihui Jin,Zhenyuan Han,Pengjun Zhao,Kun Sun
标识
DOI:10.2174/0929867329666220216110931
摘要
The current coronavirus disease 2019 (COVID-19) pandemic, since first reported in Wuhan, has inspired worldwide efforts to develop effective COVID-19 vaccination strategies. mRNA vaccines encoding COVID-19 antigens gain lead in this global race due to their high effectiveness and simple manufacturing process. Notably, two COVID-19 mRNA vaccines, mRNA-1273 and BNT162b2, have survived in clinical trials and been authorized for emergency use across a range of countries.Recent advances on mRNA vaccine development for COVID-19 are discussed in this perspective, including sequence design, chemical modification, manufacturing process and in vivo delivery. Phase I to IV clinical trials of mRNA-1273 and BNT162b2 are then summarized, respectively.Using mRNA vaccines serves as a promising strategy to achieve mass vaccination in the COVID-19 pandemic. We hope that future studies of mRNA vaccine technology would overcome existing limitations and help people cope with COVID-19.
科研通智能强力驱动
Strongly Powered by AbleSci AI